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Histopathological differences of myotonic
dystrophy type 1 (DM1) and PROMM/DM2
A. Vihola, MSc; G. Bassez, MD; G. Meola, MD, PhD; S. Zhang, PhD; H. Haapasalo, MD, PhD;
A. Paetau, MD, PhD; E. Mancinelli, PhD; A. Rouche, MSc; J.Y. Hogrel, PhD; P. Laforêt, MD;
T. Maisonobe, MD; J.F. Pellissier, MD, PhD; R. Krahe, PhD; B. Eymard, MD, PhD; and B. Udd, MD, PhD
Abstract—Muscle biopsy findings in DM2 have been reported to be similar to those in DM1. The authors used myosin
heavy chain immunohistochemistry and enzyme histochemistry for fiber type differentiation on muscle biopsies. Their
results show that DM2 patients display a subpopulation of type 2 nuclear clump and other very small fibers and, hence,
preferential type 2 fiber atrophy in contrast to type 1 fiber atrophy in DM1 patients.
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Myotonic dystrophies are categorized as DM1 (myo-
tonic dystrophy, Steinert’s disease; OMIM 160900),
caused by a (CTG)n expansion mutation in 19q13,
and DM2 (proximal myotonic myopathy [PROMM];
OMIM 602668), caused by a (CCTG)n expansion mu-
tation in 3q21.1,2 Both myotonic dystrophies are auto-
somal dominant multiorgan syndromes with striking
similarities in clinical manifestations and muscle
histopathology.3-5 Distinct features of DM2 compared
with DM1 include preferentially proximal muscle
weakness and muscle biopsy type 1 fiber predomi-
nance, higher frequency of nuclear clump fibers, and
lack of type 1 fiber atrophy as seen in DM1.6-8 The
possibility of type 2 fiber atrophy has been raised
with DM2.9 We studied the histopathology of DM1
and DM2.
Patients and methods. Deltoid, biceps brachii, and vastus
lateralis muscle biopsies from nine patients from three European
countries were re-examined. All had PROMM phenotype and ex-
panded DM2 alleles in the range of 5 to 25 kb as assessed by
Southern analysis. The biopsies were previously taken for diag-
nostic purposes and used for this study after informed consent
from the patients. The Table provides a description of clinical
features of the DM2 patients in this study. Electromyography
(EMG) showed myotonia for all patients.
Muscle biopsies. Deltoid muscle biopsies were obtained from
three French DM2 patients, two of whom originated from France
and one from Serbia. Detailed clinical features of one patient (F3)
from the series have been previously reported.9 Vastus lateralis
muscle biopsies from three patients from two unrelated Finnish
DM2 families not previously reported were examined (FIN1 and
FIN3 are cousins). Biceps brachii muscle biopsies were obtained
from three patients from unrelated Italian DM2 families. Control
subjects were age-matched and mutation-verified DM1 patients
from different families (deltoid, three; vastus, three; biceps, two),
with similar muscle weakness shown on muscle biopsy, and one
recessive congenital myotonia patient with homozygous R894X
mutation in the CLCN1 gene.
Histologic procedure. Serial transverse muscle cryostat sec-
tions 6 m and 10 m thick were cut for immunohistochemical
(IHC) and routine histochemical stainings, respectively, with he-
matoxylin and eosin (H-E), Gomori’s trichrome, and nicotinamide
adenine dinucleotide (NADH) tetrazolium reductase.10 A standard
myofibrillar ATPase staining protocol was used after preincuba-
tion at pH 4.3, pH 4.6, and pH 9.4 or 10.4.10 Ventana Nexes
automated immunostainer (Ventana Medical Systems, Tucson,
AZ) was used for IHC, with avidin-biotin-complex method followed
by diaminobenzidine (DAB) detection. Monoclonal primary anti-
bodies against different myosin heavy chain (MHC) isotypes were
used at the following dilutions: MHCfast, 1:400 (My-32, Sigma
Chemical Co., St. Louis, MO); MHCslow, 1:5,000 (NOQ7.5.4D,
Sigma); and MHCd (developmental), 1:10 (RNMy2/9D2, Novocas-
tra Laboratories, Newcastle upon Tyne, UK). Quantitative evalu-
ation of fiber diameter was made with Scion Image (Scion
Corporation, Frederick, MD) on images taken with a microscope
(3.2  10 original magnification) and sections stained with slow
and fast MHC IHC. The size of muscle fibers was assessed by
measuring the “smallest fiber diameter.” The number of muscle
fibers evaluated in each sample ranged from 537 to 5,151 (see
supplementary content on the Neurology Web site). All data were
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elaborated using Microcal Origin (Microcal Software Inc.,
Northampton, MA). The metahistograms were normalized to nor-
mal mean diameter for men and women. Atrophy and hypertrophy
factors were also calculated.10
Results. Common histopathologic findings. Routine histo-
chemical stainings of DM2 muscle sections showed myopathic
changes, including increased fiber size variation and internalized
nuclei (figure 1). Increases of connective tissue, fat replacement,
or necrotic fibers were rarely observed. Structural changes mainly
consisted of occasional moth-eaten fibers, whereas subsarcolem-
mal masses and ring fibers were particularly rare. Occasional
rimmed vacuolar fibers or ragged-red fibers (RRF) were encoun-
tered in some specimens. Central nuclei were frequent in DM1
and DM2 biopsies, and many small fibers with nuclear clumps
were observed in most DM2 specimens (see figure 1). Rounded or
thin angular atrophic fibers were usually scattered, whereas fiber
type grouping or targetoid fibers were not encountered.
Figure 1. Panel showing vastus latera-
lis histopathology of DM2 compared
with DM1. (A through D) Finnish DM2
Patient FIN1. (E and F) Italian DM1
patient. (A) Hematoxylin and eosin (H-
E); (B) ATPase pH 10.4; (C) Immuno-
histochemical (IHC), MHCslow; (D)
IHC, MHCfast; (E) IHC, MHCslow; and
(F) IHC, MHCfast. The population of
small type 2 fibers in DM2 muscle is
more distinguishable when IHC stain-
ing is used instead of ATPase. In the
DM1 control muscle, no population of
small fibers of either type is present.
Arrows indicate nuclear clump fibers.
Scale bar  100 m.
Table Clinical findings of the DM2 patients included in this study
Patient
Sex
M/F Age
Onset
age
First
symptom
Clinical muscle
signs Systemic signs
Other
findings
Biopsied muscle
(MRC score)
French
F1 M 49 40 Wk Wk Ca, B, Hy — Deltoid (4)
F3 M 45 41 Wk Wk, P Ca, B, D, IR, Hy, G At,
HCh
Deltoid (4)
F4 M 57 55 P Wk, P Ca, Hy Tr Deltoid (5)
Finnish
FIN1 M 39 36 CK Wk Ca HCh Vastus lateralis (5)
FIN2 F 34 27 St — — — Vastus lateralis (5)
FIN3 F 42 32 St, Ca Wk Ca — Vastus lateralis (5)
Italian
I1 F 60 40 Wk Wk, My Ca — Biceps brachii (4)
I2 M 57 50 Wk Wk, My Ca — Biceps brachii (5)
I3 M 59 45 Wk, P Wk Ca — Biceps brachii (5)
At  severe atherosclerosis; B  balding; Ca  cataracts; CK  serum CK elevation; D  diabetes mellitus; G  elevated gamma glu-
tamyltransferase; HCh  hypercholesterolemia; Hy  hyperhidrosis; IR  insulin resistance; My  clinical myotonia; P  pain; Pt 
ptosis; St  stiffness; Tr  tremor; Wk  weakness.
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Fiber type analysis. The metahistograms based on IHC data
in figure 2 show preferential fiber type 2 atrophy in vastus latera-
lis, biceps, and deltoid muscles from DM2 patients. Hypertrophy
of type 2 fibers in biceps of DM2 patients is also evident. In DM1
patients, marked atrophy of type 1 fibers and slight atrophy of
type 2 fibers are present in all muscles. A control sample from the
recessive congenital myotonia patient revealed no preferential
type 2 atrophy (data not shown). A subpopulation of small fibers
(diameter  20 m), including all the nuclear clump fibers (which
expressed almost exclusively fast MHC [type 2 fiber] isoform), was
seen in the DM2 biopsies. Nuclear clumps and other small type 2
fibers were prominent in some vastus lateralis and deltoid sam-
ples even at onset of symptoms. IHC and the ATPase method gave
identical fiber type distribution patterns for fibers more than 40
m in diameter, but many fibers less than 20 m in diameter,
well identified by MHC IHC, were not readily discernible with
H-E and ATPase (see figure 1). A small proportion of fibers of all
sizes expressed fast and slow MHC isoforms, and few regenerating
fibers expressing the developmental myosin isotype were ob-
served. The presence of 2B fibers was confirmed in all DM2 biop-
sies in this study, although not in constant proportions (see table
E-1 on the Neurology Web site for a summary of the key figures of
the histographic analysis). The calculated atrophy and hypertro-
phy factors are in full agreement with the results derived from
other methods in this study.
Discussion. Our study shows preferential type 2 fi-
ber atrophy in DM2 and absence of type 1 fiber atrophy
in contrast to DM1. IHC determination of fiber type
distribution revealed many small fibers (diameter  20
m), including the nuclear clump fibers, practically all
of which were identified as type 2 fibers. This study
showed a variable fiber type distribution in DM2 de-
pending on muscle site. In particular, the previously
described type 1 fiber predominance was only attested
in deltoid biopsies and was not confirmed in vastus
lateralis and biceps brachii muscles. Hypertrophy was
variable in both fiber types, which may be the result of
secondary compensation or myotonia.
Further studies will be required to determine the
fiber type of nuclear clump fibers appearing in more
Figure 2. Metahistograms showing the
preferential atrophy of type 2 fibers in
vastus lateralis, biceps, and deltoid
muscles from DM2 patients, and
marked type 1 fiber atrophy and slight
type 2 atrophy in DM1 patients. The
results are based on IHC stained sec-
tions. Atrophy (A) and hypertrophy (H)
factors for type 1 and type 2 fibers: vas-
tus lateralis; DM2 vs DM1: A1, 70.91 vs
227.01; A2, 739.64 vs 247.36; H1,
473.56 vs 100.31; H2, 100.33 vs 270.45;
biceps; DM2 vs DM1: A1, 18.90 vs
538.17; A2, 252.11 vs 190.48; H1,
135.43 vs 0.00; H2, 680.28 vs 11.58;
deltoid; DM2 vs DM1: A1, 152.64 vs
325.76; A2, 1,232.96 vs 180.94; H1,
179.36 vs 47.18; H2, 287.23 vs 54.55.
Upper limits for the value of atrophy
and hypertrophy factors in vastus late-
ralis: (men) A1, 150; A2, 150; H1, 150;
H2, 400; (women) A1, 100; A2, 200; H1,
400; H2, 150; and biceps (men) A1, 150;
A2, 150; H1, 300; H2, 500; (women) A1,
100; A2, 150; H1, 200; H2, 150.10
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severely affected DM1 muscles and whether the dif-
ferent extremely small type 2 fibers in DM2 belong
to different subpopulations.
Muscle biopsy is rarely needed for DM1 diagnosis,
but for DM2 the situation is different because the
clinical findings are milder and less pathognomonic.
The histopathologic findings reported here might
help the diagnostic procedure to select patients for
further DM2 molecular genetic verification.
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A missense mutation in the mitochondrial
ND5 gene associated with a Leigh-MELAS
overlap syndrome
Marco Crimi, PhD; Sara Galbiati, MD; Isabella Moroni, MD; Andreina Bordoni, BS;
Maria Paola Perini, MD; Eleonora Lamantea, PhD; Monica Sciacco, MD; Massimo Zeviani, MD;
Ida Biunno, PhD; Maurizio Moggio, MD; Guglielmo Scarlato, MD†; and Giacomo Pietro Comi, MD
Abstract—A 13084 A-T missense mutation in the mitochondrial ND5 gene was identified in a 16-year-old boy affected
with a progressive neurodegenerative disorder combining features of Leigh and MELAS (mitochondrial encephalomyopa-
thy, lactic acidosis, and strokelike episodes) syndromes. Muscle biopsy analysis revealed partial complex I deficiency. The
mutation presented a variable degree of heteroplasmy in the patient’s tissues. This finding underlines the contribution of
mtDNA-encoded complex I subunits in the etiology of complex I deficiency associated with encephalopathy.
NEUROLOGY 2003;60:1857–1861
Isolated complex I deficiency is a common enzyme
defect among the group of oxidative phosphorylation
disorders.1 Human complex I consists of at least 36
nuclear DNA (nDNA)- and 7 mitochondrial DNA
(mtDNA)-encoded subunits. Leigh syndrome (LS) or
Leigh-like disease is the most common phenotype
associated with an isolated complex I deficiency, rep-
resenting up to 50% of total cases, although isolated
myopathies, MELAS (mitochondrial encephalomy-
opathy, lactic acidosis, and strokelike episodes) syn-
drome, and Leber’s hereditary optic neuropathy
(LHON) presentations are also described.1
Here we report a novel ND5 heteroplasmic mis-
sense mutation associated with severe progressive
infantile encephalopathy, with features of LS and
MELAS. The proband’s mother, carrying a lower mu-
tation level, presents recurrent migraine attacks and
bilateral optic atrophy. These data expand the mo-
lecular etiology of partial isolated complex I
deficiency.
† Deceased.
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